Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Eur Urol Oncol. 2021 Apr 15;4(4):532–539. doi: 10.1016/j.euo.2021.03.006

Table 2.

Biochemical recurrence–free survival for extended versus limited PLND

Model Hazard ratio (95% CI) p value
All evaluable patients (n = 1440) 0.5
Patients enrolled after June 2015 (n = 431) 1.18 (0.76–1.86) 0.5
Meta-analysis combining results from before and after cluster randomization began in June 2012 (n = 1440) 1.03 (0.94–1.13) 0.8
Model adjusted for PSA, biopsy grade group, and clinical stage (n = 1339) 0.95 (0.84–1.07) 0.4

CI = confidence interval; PLND = pelvic lymph node dissection; PSA = prostate-specific antigen.